Cargando…

Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)

Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients withou...

Descripción completa

Detalles Bibliográficos
Autores principales: Teichmann, J, Lange, U, Discher, T, Lohmeyer, J, Stracke, H, Bretzel, RG
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351961/
https://www.ncbi.nlm.nih.gov/pubmed/19258214
http://dx.doi.org/10.1186/2047-783X-14-2-59
_version_ 1782232818368118784
author Teichmann, J
Lange, U
Discher, T
Lohmeyer, J
Stracke, H
Bretzel, RG
author_facet Teichmann, J
Lange, U
Discher, T
Lohmeyer, J
Stracke, H
Bretzel, RG
author_sort Teichmann, J
collection PubMed
description Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART.
format Online
Article
Text
id pubmed-3351961
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-33519612012-05-16 Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART) Teichmann, J Lange, U Discher, T Lohmeyer, J Stracke, H Bretzel, RG Eur J Med Res Research Alterations of bone metabolism have been observed in numerous studies of HIV-infected patients. Sex steroids are known to profoundly influence bone mass and bone turnover. Hypogonadism is common in HIV-infection. Therefore, we performed a cross sectional study of 80 male HIV-infected patients without wasting syndrome, and 20 healthy male controls, in whom we analyzed urine and serum samples for both calciotropic hormones and markers of bone metabolism and of endocrine testicular function. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry both in the lumbar spine and Ward's triangle of the left hip. None of the patients received highly-active-antiretroviral-therapy (HAART). Compared to eugonadal HIV-infected patients, subjects with hypogonadism (n = 32; 40%) showed statistically significant decrease of serum osteocalcin (p < 0.05) and elevated urinary excretion of crosslinks (p < 0.05). However, we found 13 and 15, respectively, patients with osteopenia (t-score -1.0 to -2.5 SD below normal) of the lumbar spine. The dissociation between bone formation and resorption and the reduction of of BMD (p < 0.05) is stronger expressed in patients with hypogonadism. Habitual hypogonadism appears to be of additional relevance for bone metabolism of male HIV-positive patients prior to HAART. BioMed Central 2009-02-18 /pmc/articles/PMC3351961/ /pubmed/19258214 http://dx.doi.org/10.1186/2047-783X-14-2-59 Text en Copyright ©2009 I. Holzapfel Publishers
spellingShingle Research
Teichmann, J
Lange, U
Discher, T
Lohmeyer, J
Stracke, H
Bretzel, RG
Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title_full Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title_fullStr Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title_full_unstemmed Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title_short Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART)
title_sort bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (haart)
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3351961/
https://www.ncbi.nlm.nih.gov/pubmed/19258214
http://dx.doi.org/10.1186/2047-783X-14-2-59
work_keys_str_mv AT teichmannj bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart
AT langeu bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart
AT dischert bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart
AT lohmeyerj bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart
AT strackeh bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart
AT bretzelrg bonemineraldensityinhumanimmunodeficiencyvirus1infectedmenwithhypogonadismpriortohighlyactiveantiretroviraltherapyhaart